Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.58 |
| ▸ | KDR | P35968 | 6/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594061 | 0.95 | DDR2 (0.66) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130416 | 0.89 | DDR2 (0.65) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130139 | 0.89 | DDR2 (0.65) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL13078259 | 0.89 | DDR2 (0.62) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130144 | 0.88 | MAPK14 (0.62) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130398 | 0.88 | DDR2 (0.70) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL594298 | 0.88 | DDR2 (0.67) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130126 | 0.88 | DDR2 (0.61) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130447 | 0.88 | MAPK14 (0.61) | DDR2MAPK14KDRMAPK13MAPK12 | |
| SCHEMBL10130100 | 0.88 | MAPK14 (0.62) | DDR2MAPK14KDRMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK7, MAP3K1 | DDR2 3028/4885MAPK14 15/4885KDR 4065/4885 |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK8, MAPK4 | DDR2 3203/4885MAPK14 10/4885KDR 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.